GRPH - Graphite Bio sinks 45% on halting early-stage trial of sickle cell candidate
- Graphite Bio ( NASDAQ: GRPH ) sank 45% in after-hours trading on Thursday after announcing that it was voluntarily pausing a phase 1/2 study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease following a serious adverse event in the first patient treated.
- The biotech said the event was likely due to nula-cel.
- The adverse event was prolonged low blood cell counts (pancytopenia) that required ongoing transfusion and growth factor support.
- Graphite Bio ( GRPH ) said it will miss its guidance for initial proof-of-concept data in mid-2023.
- Also, the company no longer anticipates filing an investigational new drug application for GPH102 in beta-thalassemia by mid-2024.
For further details see:
Graphite Bio sinks 45% on halting early-stage trial of sickle cell candidate